1. O-010Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program. (20th June 2018) Authors: Moehler, M; Maderer, A; Thuss-Patience, P; Brenner, B; Hecker, J; Muñoz, F Longo; Meiler, J; Ettrich, T; Hofheinz, R; Al-Batran, S; Vogel, A; Mueller, L; Lutz, M; Borchert, K; Greil, R; Alsina, M; Karatas, A; Van Cutsem, E; Keller, R; Larcher-Senn, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P013 Role of IL-36RA mutations in Crohn's disease. (30th January 2023) Authors: Hecker, J; Saurenbach, J; Letizia, M; Löscher, B S; Franke, A; Kühl, A A; Atreya, R; Koop, K; Neufert, C; Trajanoski, Z; Schütz, A; Siegmund, B; Weidinger, C Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P048 Deep phenotyping of the peripheral immune cell compartment in Crohn's Disease. (30th January 2023) Authors: Haag, L M; Walling, S; Kunkel, D; Hecker, J; Letizia, M; Huck, A; Weidinger, C; Glauben, R; Kuehl, A; Siegmund, B Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P058 IL-36 signaling in Crohn's disease – characterization of a patient with an IL36RA mutation. (21st January 2022) Authors: Hecker, J; Letizia, M; Loescher, B S; Franke, A; Weidinger, C; Siegmund, B Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗